T-cell Acute Lymphoblastic Leukemia: Clinical Trials

11 trials for T-cell Acute Lymphoblastic Leukemia, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

8 recruiting, 2 not yet recruiting, 1 completed. 11 Phase 2, 5 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 211Recruiting 8, Not yet recruiting 2, Completed 1
Phase 15Not yet recruiting 2, Recruiting 2, Completed 1

Follow T-cell Acute Lymphoblastic Leukemia: new trials by email Literature Review of T-cell Acute Lymphoblastic Leukemia trials Research Report on T-cell Acute Lymphoblastic Leukemia

Trials (filtered) newest first · largest first

All 11 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Multi-CAR T Cell Therapy Targeting CD7-positive Malignancies
CD7-specific CAR gene-engineered T cells - T-cell Acute Lymphoblastic Leukemia, T-cell Acute Lymphoblastic Lymphoma
Phase 1 / Phase 2Not yet recruitingShenzhen Geno-Immune Medical Institute302026-12-312026-11-02
A Multicenter, Open-label, Non-randomized, Single-arm Phase 1/2 Study of Autologous Nano CD5-CAR T Cells for the Treatment of Relapsed/Refractory T-cell Acute Lymphoblastic Leukemia/Lymphoma
Autologous nano CD5-CAR T Cells - T-Cell Acute Lymphoblastic Leukemia, T-Lymphoblastic Lymphoma
Phase 1 / Phase 2Not yet recruitingInstitute of Hematology & Blood Diseases Hospital, China182026-06-302026-07-01
A Phase 2 Study to Evaluate Efficacy of Calaspargase Pegol-mknl and Decitabine Combined With Venetoclax in Pediatric, Adolescent, and Young Adult Patients With Relapsed/Refractory T-cell Acute Lymphoblastic Leukemia (T-ALL) and T- Cell Lymphoblastic Lymphoma (T-LLy)
Decitabine, Venetoclax, Calaspargase pegol-mknl - T-cell Acute Lymphoblastic Leukemia, T-Cell Lymphoblastic Lymphoma
Phase 2RecruitingM.D. Anderson Cancer Center222025-09-252026-09-18
A Phase 2 Study of WU-CART-007, an Anti-CD7 Allogeneic CAR-T Cell Therapy in T-Cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma (T-RRex)
WU-CART-007 - T-cell Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma
Phase 2RecruitingAllotera Therapeutics1252025-01-312026-09-28
Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL)
Dexamethasone, Vincristine, Daunorubicin - T-cell Acute Lymphoblastic Leukemia, T-cell Lymphoma
Phase 2RecruitingSt. Jude Children's Research Hospital1002024-12-272026-08-10
Demethylating Agents Combined With Venetoclax for High-risk T-cell Lymphoblastic Lymphoma/Leukemia Post-Transplant Relapse Prevention
Azacitidine (AZA) Days 1 - 5, Decitabine (DAC), Venetoclax - T-cell Acute Lymphoblastic Leukemia, ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION
Phase 2RecruitingShanghai General Hospital, Shanghai Jiao Tong University School of Medicine592024-10-302025-05-07
Sequential CAR-T Cells Therapy for CD5/CD7 Positive T-cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma Using CD5/CD7-Specific CAR-T Cells
CD5/CD7 CAR-T - T Cell Lymphoma, T Cell Leukemia
Phase 1 / Phase 2RecruitingEssen Biotech602024-07-102024-11-12
Autologous and Donor-derived CD7 CAR-T Therapy in Refractory or Relapsed T-cell Malignancies
Autologous CD7 CAR T-cell, Prior-HSCT donor-derived CD7 CAR T-cell, New donor-derived CD7 CAR T-cell - T-cell Acute Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia, in Relapse
Phase 1 / Phase 2RecruitingBeijing GoBroad Hospital802024-03-222025-11-26
Daratumumab for Chemotherapy-Refractory Minimal Residual Disease in T Cell ALL
Daratumumab / Hyaluronidase Injection - T-cell Acute Lymphoblastic Leukemia
Phase 2RecruitingEastern Cooperative Oncology Group202023-05-252026-11-16
Study of Venetoclax Combined With Azacitidine Regimen in Newly Diagnosed T-ALL Patients
Venetoclax, Azacitidine - T-cell Acute Lymphoblastic Leukemia, Recruiting
Phase 2RecruitingThe First Affiliated Hospital of Soochow University282022-04-012026-03-19
A Study of LY3039478 in Combination With Dexamethasone in Participants With T-ALL/T-LBL
LY3039478, Dexamethasone, Placebo - T-cell Acute Lymphoblastic Leukemia, T-cell Lymphoblastic Lymphoma
Phase 1 / Phase 2CompletedEli Lilly and Company362015-10-012019-09-11

Narrower conditions

Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (11)  ·  Lymphoma, T-Cell (2)  ·  Precursor Cell Lymphoblastic Leukemia-Lymphoma (2)  ·  Hematologic Neoplasms (1)  ·  Leukemia (1)  ·  Leukemia, Biphenotypic, Acute (1)  ·  Leukemia, Myeloid, Acute (1)  ·  Leukemia, Prolymphocytic, T-Cell (1)  ·  Leukemia, T-Cell (1)  ·  Recurrence (1)

Broader conditions

Hematologic Diseases (11)  ·  Hemic and Lymphatic Diseases (11)  ·  Immune System Diseases (11)  ·  Immunoproliferative Disorders (11)  ·  Leukemia, Lymphoid (11)  ·  Lymphatic Diseases (11)  ·  Lymphoproliferative Disorders (11)  ·  Neoplasms (11)  ·  Neoplasms by Histologic Type (11)  ·  Leukemia (10)  ·  Precursor Cell Lymphoblastic Leukemia-Lymphoma (9)  ·  Lymphoma (2)  ·  Lymphoma, Non-Hodgkin (2)  ·  Disease Attributes (1)  ·  Leukemia, Myeloid (1)

Interventions

venetoclax (4)  ·  Azacitidine (2)  ·  Decitabine (2)  ·  Dexamethasone (2)  ·  calaspargase pegol (2)  ·  Bortezomib (1)  ·  Calcium Dobesilate (1)  ·  Cyclophosphamide (1)  ·  Cytarabine (1)  ·  Dasatinib (1)  ·  Daunorubicin (1)  ·  Hyaluronoglucosaminidase (1)  ·  Hydrocortisone (1)  ·  Mercaptopurine (1)  ·  Methotrexate (1)

Sponsors

Allotera Therapeutics (1)  ·  Beijing GoBroad Hospital (1)  ·  Eastern Cooperative Oncology Group (1)  ·  Eli Lilly and Company (1)  ·  Essen Biotech (1)  ·  Institute of Hematology & Blood Diseases Hospital, China (1)  ·  M.D. Anderson Cancer Center (1)  ·  Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine (1)  ·  Shenzhen Geno-Immune Medical Institute (1)  ·  St. Jude Children's Research Hospital (1)  ·  The First Affiliated Hospital of Soochow University (1)

Countries

China (5)  ·  United States (5)  ·  Australia (1)  ·  France (1)  ·  Germany (1)  ·  Israel (1)  ·  Italy (1)

Top investigators

Cherry Thomas, MD (1)  ·  David McCall, MD (1)  ·  Seth E. Karol, MD, MSCI (1)  ·  Shira Dinner, MD (1)

Results publications

PMID 33107983, PMID 41619724

NIH funding

2014 (1)